Quince Therapeutics shares rise 10.65% premarket after eliminating $16.4M EIB debt with $5.5M payment.

Quince Therapeutics surged 10.65% in premarket trading following the announcement that it fully repaid approximately $16.4 million in outstanding debt to the European Investment Bank for about $5.5 million. The debt settlement, completed on March 27, 2026, is expected to enhance the company’s financial flexibility and reduce future obligations, likely contributing to the positive premarket reaction.